181 related articles for article (PubMed ID: 35467350)
1. Investigation of Tumor Cells and Receptor-Ligand Simulation Models for the Development of PET Imaging Probes Targeting PSMA and GRPR and a Possible Crosstalk between the Two Receptors.
Liolios C; Patsis C; Lambrinidis G; Tzortzini E; Roscher M; Bauder-Wüst U; Kolocouris A; Kopka K
Mol Pharm; 2022 Jul; 19(7):2231-2247. PubMed ID: 35467350
[TBL] [Abstract][Full Text] [Related]
2. Monomeric and Dimeric
Liolios C; Buchmuller B; Bauder-Wüst U; Schäfer M; Leotta K; Haberkorn U; Eder M; Kopka K
J Med Chem; 2018 Mar; 61(5):2062-2074. PubMed ID: 29432691
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.
Bandari RP; Jiang Z; Reynolds TS; Bernskoetter NE; Szczodroski AF; Bassuner KJ; Kirkpatrick DL; Rold TL; Sieckman GL; Hoffman TJ; Connors JP; Smith CJ
Nucl Med Biol; 2014 Apr; 41(4):355-63. PubMed ID: 24508213
[TBL] [Abstract][Full Text] [Related]
4. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
5. Novel Bispecific PSMA/GRPr Targeting Radioligands with Optimized Pharmacokinetics for Improved PET Imaging of Prostate Cancer.
Liolios C; Schäfer M; Haberkorn U; Eder M; Kopka K
Bioconjug Chem; 2016 Mar; 27(3):737-51. PubMed ID: 26726823
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of a novel urea-based
Zha Z; Ploessl K; Choi SR; Wu Z; Zhu L; Kung HF
Nucl Med Biol; 2018 Apr; 59():36-47. PubMed ID: 29459281
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer.
Eder M; Schäfer M; Bauder-Wüst U; Haberkorn U; Eisenhut M; Kopka K
Prostate; 2014 May; 74(6):659-68. PubMed ID: 24464532
[TBL] [Abstract][Full Text] [Related]
8. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.
Eder M; Schäfer M; Bauder-Wüst U; Hull WE; Wängler C; Mier W; Haberkorn U; Eisenhut M
Bioconjug Chem; 2012 Apr; 23(4):688-97. PubMed ID: 22369515
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of peptide-based imaging agents [
Zhang-Yin J; Provost C; Cancel-Tassin G; Rusu T; Penent M; Radulescu C; Comperat E; Cussenot O; Montravers F; Renard-Penna R; Talbot JN; Prignon A
Nucl Med Biol; 2020; 84-85():88-95. PubMed ID: 32251995
[TBL] [Abstract][Full Text] [Related]
10. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA
Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and Evaluation of
Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and pre-clinical evaluation of a new class of high-affinity
Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and in vitro proof-of-concept studies on bispecific iron oxide magnetic nanoparticles targeting PSMA and GRP receptors for PET/MR imaging of prostate cancer.
Liolios C; Koutsikou TS; Salvanou EA; Kapiris F; Machairas E; Stampolaki M; Kolocouris A; Efthimiadou EΚ; Bouziotis P
Int J Pharm; 2022 Aug; 624():122008. PubMed ID: 35820513
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo evaluation of the bifunctional chelator NODIA-Me in combination with a prostate-specific membrane antigen targeting vector.
Läppchen T; Kiefer Y; Holland JP; Bartholomä MD
Nucl Med Biol; 2018 May; 60():45-54. PubMed ID: 29571066
[TBL] [Abstract][Full Text] [Related]
15. Validation of a [Al
Al-Momani E; Israel I; Samnick S
Appl Radiat Isot; 2017 Dec; 130():102-108. PubMed ID: 28950199
[TBL] [Abstract][Full Text] [Related]
16. PET Probes for Preclinical Imaging of GRPR-Positive Prostate Cancer: Comparative Preclinical Study of [
Kálmán-Szabó I; Szabó JP; Arató V; Dénes N; Opposits G; Jószai I; Kertész I; Képes Z; Fekete A; Szikra D; Hajdu I; Trencsényi G
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077458
[TBL] [Abstract][Full Text] [Related]
17. What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake.
Kuo HT; Lin KS; Zhang Z; Zhang C; Merkens H; Tan R; Roxin A; Uribe CF; Bénard F
Theranostics; 2022; 12(14):6179-6188. PubMed ID: 36168623
[TBL] [Abstract][Full Text] [Related]
18. Radiometal Complexes as Pharmacokinetic Modifiers: A Potent
Schreck MV; Burgard C; Schmidtke A; Hierlmeier I; Stemler T; Maus S; Rosar F; Jung M; Speicher A; Ezziddin S; Holland JP; Bartholomä MD
Mol Pharm; 2023 Dec; 20(12):6463-6473. PubMed ID: 37978936
[TBL] [Abstract][Full Text] [Related]
19. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
[TBL] [Abstract][Full Text] [Related]
20. (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer.
Liu Z; Yan Y; Liu S; Wang F; Chen X
Bioconjug Chem; 2009 May; 20(5):1016-25. PubMed ID: 20540537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]